Consequently, PRMT5 has emerged as a critical therapeutic target in numerous malignancies, with small molecule inhibitors designed to reduce PRMT5 activity currently undergoing clinical trials, particularly in solid tumors and hematological cancers characterized by MTAP deletion (13, 17). Here, PRMT5 is linked to hematopoietic and lymphoid cell neoplasm.